%0 Journal Article
%A Schmidt, Teresa
%A Agkatsev, Sarina
%A Feldheim, Jonas
%A Oster, Christoph
%A Blau, Tobias
%A Sure, Ulrich
%A Keyvani, Kathy
%A Kleinschnitz, Christoph
%A Stuschke, Martin
%A Herrmann, Ken
%A Deuschl, Cornelius
%A Scheffler, Björn
%A Kebir, Sied
%A Glas, Martin
%A Lazaridis, Lazaros
%T Feasibility and tolerability of trofosfamide and etoposide in progressive glioblastoma.
%J Neuro-oncology advances
%V 5
%N 1
%@ 2632-2498
%C Oxford
%I Oxford University Press
%M DKFZ-2023-01598
%P vdad090
%D 2023
%X Standard of care treatment options at glioblastoma relapse are still not well defined. Few studies indicate that the combination of trofosfamide plus etoposide may be feasible in pediatric glioblastoma patients. In this retrospective analysis, we determined tolerability and feasibility of combined trofosfamide plus etoposide treatment at disease recurrence of adult glioblastoma patients.We collected clinicopathological data from adult progressive glioblastoma patients treated with the combination of trofosfamide and etoposide for more than four weeks (one course). A cohort of patients receiving empiric treatment at the investigators' discretion balanced for tumor entity and canonical prognostic factors served as control.A total of n = 22 progressive glioblastoma patients were eligible for this analysis. Median progression-free survival (3.1 vs 2.3 months, HR: 1.961, 95
%K etoposide (Other)
%K glioblastoma (Other)
%K progressive glioblastoma (Other)
%K trofosfamide (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:37547266
%2 pmc:PMC10403750
%R 10.1093/noajnl/vdad090
%U https://inrepo02.dkfz.de/record/278341